| Filed On | Filing |
|---|---|
| 14 Dec 2023 |
8-K/A: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure
Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer |
| 21 Dec 2017 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 14 Nov 2016 |
8-K/A: Other Events
NEW YORK, NY, November 14, 2016 — Pfizer Inc. (NYSE: PFE) today announced the commencement of a tender offer (the “Tender Offer”) to purchase for cash any and all of its outstanding 6.200% Senior Notes due March 15, 2019 (the “Notes”). C... |
| 30 Jun 2003 | 8-K/A: Completion of Acquisition or Disposition of Assets |
| 28 Apr 2003 |
8-K/A: Changes in Registrant's Certifying Accountant
Securities and Exchange Commission 450 Fifth Street, N. W. Washington, D. C. 20549 |
| 10 May 1995 |
8-K/A: Financial Statements and Exhibits
-------------------------------------------------------------------------------- -------------------------------------------------------------------------------- |
Loading...